文献速递肝病

FMO2通过抑制SREBP1从内质网到高尔基体的转运改善非酒精性脂肪性肝病

FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1.
PubMed 文献 · Hepatology · 2023-10-24

本研究探讨黄素单氧化酶2(FMO2)在非酒精性脂肪性肝病(NAFLD)中的作用。发现FMO2在NAFL/NASH患者和小鼠模型中表达下调,其缺失加重脂肪生成和肝脂肪变性、炎症和纤维化,而过表达改善NAFL/NASH;机制上FMO2与SREBP1直接结合并竞争性抑制SCAP,阻止SREBP1从内质网向高尔基体转位及激活,从而抑制从头脂肪生成。

要点

  • FMO2在NAFL/NASH患者和小鼠模型中表达显著下调。
  • FMO2缺失加重肝脂肪变性、炎症和纤维化,过表达则改善。
  • FMO2通过结合SREBP1并阻止其从内质网向高尔基体转位抑制脂肪生成。

核心结论

  • FMO2是保护NAFL/NASH进展的新型分子,且不依赖酶活性。
  • FMO2通过直接结合SREBP1并阻止其细胞器转位和激活,抑制高脂饮食或胆碱缺乏、甲硫氨酸缺乏、氨基酸定义的高脂饮食诱导的脂肪变性、炎症和纤维化。
  • FMO2是靶向SREBP1激活和治疗NAFL/NASH的有前景的分子。

研究设计与样本

  • 研究采用NAFL/NASH患者和小鼠模型,结合全局和肝细胞特异性敲除及过表达实验。
  • 通过RNA测序和机制实验分析FMO2与SREBP1的相互作用。

主要发现

  • FMO2在NAFL/NASH患者和小鼠模型中表达显著下调。
  • 全局和肝细胞特异性敲除FMO2导致脂肪生成增加和严重的肝脂肪变性、炎症和纤维化,而过表达FMO2改善NAFL/NASH。
  • RNA测序显示肝FMO2缺乏与代谢挑战下脂肪生成受损相关。
  • 机制上FMO2在氨基酸217-296处与SREBP1直接相互作用,竞争性抑制SREBP裂解激活蛋白(SCAP),抑制SREBP1从内质网向高尔基体转位及后续激活,从而抑制从头脂肪生成并改善NAFL/NASH。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD comprises a spectrum of liver disorders with the initial abnormal accumulation of lipids in hepatocytes called NAFL, progressing to the more serious NASH in a subset of individuals. Our previous study revealed that global flavin-containing monooxygenase 2 (FMO2) knockout causes higher liver weight in rats. However, the role of FMO2 in NAFLD remains unclear. Herein, we aimed to determine the function and mechanism of FMO2 in liver steatosis and steatohepatitis. APPROACH AND RESULTS: The expression of FMO2 was significantly downregulated in patients with NAFL/NASH and mouse models. Both global and hepatocyte-specific knockout of FMO2 resulted in increased lipogenesis and severe hepatic steatosis, inflammation, and fibrosis, whereas FMO2 overexpression in mice improved NAFL/NASH. RNA sequencing showed that hepatic FMO2 deficiency is associated with impaired lipogenesis in response to metabolic challenges. Mechanistically, FMO2 directly interacts with SREBP1 at amino acids 217-296 competitively with SREBP cleavage-activating protein (SCAP) and inhibits SREBP1 translocation from the endoplasmic reticulum (ER) to the Golgi apparatus and its subsequent activation, thus suppressing de novo lipogenesis (DNL) and improving NAFL/NASH. CONCLUSIONS: In hepatocytes, FMO2 is a novel molecule that protects against the progression of NAFL/NASH independent of enzyme activity. FMO2 impairs lipogenesis in high-fat diet-induced or choline-deficient, methionine-deficient, amino acid-defined high-fat diet-induced steatosis, inflammation, and fibrosis by directly binding to SREBP1 and preventing its organelle translocation and subsequent activation. FMO2 thus is a promising molecule for targeting the activation of SREBP1 and for the treatment of NAFL/NASH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ke C, Xiao C, Li J, et al. FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. Hepatology. 2023. PMID: 37874228. doi:10.1097/HEP.0000000000000643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。